Company profile for Viralgen

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Viralgen is a CDMO born as a joint venture between Askbio and Columbus Venture Partners, combining decades of technology and drug development experience in multiple platforms to support best-in-class service offerings to the gene therapy market. Viralgen was created in 2017 to respond to the unmet need for manufacturing of gene therapies, with the goal to help broaden access to these life-saving therapeutics and to contribu...
Viralgen is a CDMO born as a joint venture between Askbio and Columbus Venture Partners, combining decades of technology and drug development experience in multiple platforms to support best-in-class service offerings to the gene therapy market. Viralgen was created in 2017 to respond to the unmet need for manufacturing of gene therapies, with the goal to help broaden access to these life-saving therapeutics and to contribute to the advancement of health and human welfare around the world.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Spain
Address
Address
Parque Científico y Tecnológico de Gipuzkoa Paseo Mikeletegi, 83 20009 San S...
Telephone
Telephone
+34 943 47 77 33
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bayers-gene-and-cell-therapy-pipeline-aims-to-transform-parkinsons-oncology-rare-diseases-and-more/articleshow/124529407.cms

ECONOMICTIMES
13 Oct 2025

https://www.prnewswire.com/news-releases/viralgen-collaborates-with-trogenix-to-advance-aav-gene-therapy-for-glioblastoma-302445018.html

PR NEWSWIRE
06 May 2025

https://prnewswire.com/news-releases/viralgen-and-axovia-partner-to-manufacture-an-investigational-gene-therapy-for-retinal-dystrophy-in-bardet-biedl-syndrome-bbs-patients-302357167.html

PR NEWSWIRE
22 Jan 2025

https://www.prnewswire.com/news-releases/viralgen-partners-with-vallabhminikel-lab-and-deverman-lab-at-the-broad-institute-to-advance-gene-therapy-manufacturing-hope-for-prion-disease-302344759.html

PR NEWSWIRE
08 Jan 2025

https://viralgenvc.com/news-and-events/visit-of-lehendakari-imanol-pradales-and-his-team-to-our-facilities

PRESS RELEASE
26 Sep 2024

https://viralgenvc.com/news-and-events/inversiones-para-la-creacion-de-un-nuevo-laboratorio-de-control-de-calidad-askbio-center-of-excellence-ace

PRESS RELEASE
19 Jul 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty